Figure 5
From: Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
Anti-tumor efficacy in CD4 or CD8 T cell depleted mice and analysis of TILs. Selected groups of BALB/c mice (10/group) were injected i.p. with either anti-CD8 (A) or anti-CD4 antibodies (D) prior to tumor cell challenge and throughout the study. Mice were treated 3 times at weekly intervals starting on day 1. **P < 0.01, ****P < 0.0001 as compared to control. At the end of the study, tumors were removed and TILs were analysed by flow cytometry. CD8 (B and E) and CD4 (C and F) T cells are shown as a percentage of cells isolated from the tumors. Graphs show representative data from two independently performed experiments.